- Technical notes
- Cellartis Power Primary HEP Medium
- Cellartis DEF-CS 500 Culture System
- Cellartis Enhanced hiPS-HEP cells
- Cellartis hES-MP 002.5
- Cellartis hPS cell-derived cardiomyocytes
- Cellartis iPS Cell to Hepatocyte Differentiation System
- 3i mES/iPSC medium
- NDiff 227
- NDiff N2
- Selection guides
Cellartis DEF-CS 500 Culture System citation list
Takara Bio has over 15 years of experience in expanding, passaging, and culturing human pluripotent stem cells under the Cellartis brand. The DEF-CS 500 system is a complete solution for the easy culturing of human pluripotent stem cells in a noncolony, 2D-monolayer format. Cells grown in this system maintain pluripotency and a normal karyotype while exhibiting robust and uniform growth. Single-cell passaging enables the ability to directly isolate and expand single clones, including cells that have undergone CRISPR/Cas9 gene editing.
Read below for a citation list of studies in which the DEF-CS 500 system was used in peer-reviewed basic, translational, preclinical, and biomedical research.
- Asplund, A. et al. One Standardized Differentiation Procedure Robustly Generates Homogenous Hepatocyte Cultures Displaying Metabolic Diversity from a Large Panel of Human Pluripotent Stem Cells. Stem Cell Rev. 12:90–104 (2016).
25 different human pluripotent stem cell lines were maintained with the DEF-CS system, and their pluripotency was confirmed. Karyotyping of the stem cells maintained using the DEF-CS system for up to 29 passages showed no genetic aberrations. These stem cell lines were then successfully differentiated into functional hepatocytes.
- Boreström, C. et al. Footprint-free human induced pluripotent stem cells from articular cartilage with redifferentiation capacity: a first step toward a clinical-grade cell source. Stem Cells Transl. Med. 3:433–47 (2014).
Chondrocyte-derived and fibroblast-derived iPSCs were maintained using the DEF-CS system in a monolayer before these cells were successfully differentiated down to the chondrogenic lineage. Pluripotency of iPSCs maintained in the DEF-CS system was confirmed with immunofluorescent staining and quantitative RT-PCR.
- Boreström, C. et al. A CRISP(e)R view on kidney organoids allows generation of an induced pluripotent stem cell-derived kidney model for drug discovery. Kidney Int. 18:30356–9 (2018).
Human induced pluripotent stem cells were maintained, edited with CRISPR/Cas9, and clonally selected in the DEF-CS system. Following clonal expansion, the cells were differentiated using a 3D differentiation protocol to create kidney organoids.
- Delsing, L. et al. Barrier properties and transcriptome expression in human iPSC-derived models of the blood-brain barrier. Stem Cells 36(12):1816–1827 (2018).
Human induced pluripotent stem cells were maintained in the DEF-CS system prior to differentiation into endothelial cells.
- Funa, N. et al. B-catenin regulates primitive streak induction through collaborative interactions with SMAD2/SMAD3 and OCT4. Cell Stem Cell. 16(6):638–652 (2015).
Human embryonic stem cells were grown in DEF-CS medium prior to differentiation in order to study how β-catenin regulates differentiation.
- Gao, X. et al. A rapid and highly efficient method for the isolation, purification, and passaging of human induced pluripotent stem cells. Cell Reprogram. 20(5):282–288 (2018).
Human induced pluripotent stem cells derived from PBMCs that were reprogrammed were single-cell passaged and expanded in DEF-CS medium. Pluripotency and genetic integrity of the hiPSCs were confirmed following single-cell passaging and expansion.
- Gao, X. et al. Generation of nine induced pluripotent stem cell lines as an ethnic diversity panel. Stem Cell Res. 31:193–196 (2018).
Human induced pluripotent stem cells were maintained, passaged as single cells, and expanded in the DEF-CS system. The resulting cell lines showed normal karyotype, expressed pluripotency markers, and were able to differentiate into the three germ layers.
- Ghosheh, N. et al. Comparative transcriptomics of hepatic differentiation of human pluripotent stem cells and adult human liver tissue. Physiol Genomics. 49(8):430–446 (2017).
Human pluripotent stem cells were maintained and passaged in the DEF-CS system prior to differentiation into hepatocytes. Transcriptomics were used to monitor the proress of in vitro hepatic differentiation of hPSCs at the following developmental stages: definitive endoderm, hepatoblast, early hPSC-HEP, and mature hPSC-HEP.
- Ghosheh, N. et al. Highly synchronized expression of lineage-specific genes during in vitro hepatic differentiation of human pluripotent stem cell lines. Stem Cells Int. 2016:8648356 (2016).
Human induced pluripotent stem cells were thawed, maintained, and passaged in the DEF-CS system prior to differentiation into hepatocytes.
- Hanson, C. et al. Transplantation of human embryonic stem cells onto a partially wounded human cornea in vitro. Acta Ophthalmol. 91(2):127–130 (2013).
Human embryonic stem cells were cultured in the DEF-CS system prior to transplantation onto a damaged human cornea.
- Kamiya, A. et al. An in vitro model of polycystic liver disease using genome-edited human inducible pluripotent stem cells. Stem Cell Res. 32:17–24 (2018).
Human induced pluripotent stem cells were maintained in the DEF-CS system prior to differentiation into hepatic progenitor cells, which were used in cytotoxicity assays.
- Kia, R. et al. MicroRNA-122: a novel hepatocyte-enriched in vitro marker of drug-induced cellular toxicity. Toxicol Sci. 144(1):173–185 (2015).
Human induced pluripotent stem cells were maintained in the DEF-CS system prior to differentiaton into hepatocyte-like cells.
- Mamidi A. et al. Mechanosignalling via integrins directs fate decisions of pancreatic progenitors. Nature. 564(7734):114–118 (2018).
Undifferentiated human embryonic stem cells were maintained in the DEF-CS system prior to differentiation into pancreatic progenitors including bipotent pancreatic progenitors.
- Nguyen, D. et al. Humanizing miniature hearts through 4-flow cannulation perfusion decellularization and recellularization. Sci Rep. 8(1):7458 (2018).
Human induced pluripotent stem cells were cultured in the DEF-CS system prior to differentiation into cardiac progenitor cells and recellularization experiments.
- Norrman, K. et al. Distinct gene expression signatures in human embryonic stem cells differentiated towards definitive endoderm at single-cell level. Methods 59:59–70 (2013).
Human embryonic stem cells were maintained in the DEF-CS system before differentiation into definitive endoderm.
- Osada, N. et al. Lysine-specific demethylase 1 inhibitors prevent teratoma development from human induced pluripotent stem cells. Oncotarget. 9(5):6450–6462 (2018).
Human induced pluripotent stem cells ere cultured in the DEF-CS system prior to gain-of-function and loss-of-function studies.
- Pradip, A. et al. High content analysis of human pluripotent stem cell derived hepatocytes reveals drug induced steatosis and phospholipidosis. Stem Cells Int. 2016:2475631 (2016).
Human induced pluripotent stem cells were maintained in the DEF-CS system prior to differentiation into hepatocytes. hiPSC-derived hepatocytes were treated with various compounds known to cause hepatotoxicity through steatosis and phospholipidosis.
- Rasmussen, C. et al. Collagen type I improves the differentiation of human embryonic stem cells towards definitive endoderm. PLoS One. 10(12):e0145389 (2015).
Human embryonic stem cells were cultured in the DEF-CS system, then exposed to 487 combinations of extracellular matrix proteins to screen for combinations that promote differentiation to definitive endoderm.
- Ribeiro, D. et al. Human pancreatic islet-derived extracellular vesicles modulate insulin expression in 3D-differentiating iPSC clusters. PLoS One. 12(11):e0187665 (2017).
Human induced pluripotent stem cells were cultured in the DEF-CS system prior to iPS clustering and pancreatic differentiation.
- Säljö, K. et al. Comparison of the glycosphingolipids of human-induced pluripotent stem cells and human embryonic stem cells. Glycobiology. 27(4):291–305 (2017).
Human induced pluripotent stem cells were maintained in the DEF-CS system prior to differentiation into neuroepithelial cells.
- Sivertsson, L. et al. Hepatic differentiation and maturation of human embryonic stem cells cultured in a perfused three-dimensional bioreactor. Stem Cells Dev. 22(4):581–594 (2012).
Human embryonic stem cells (Y00025) were cultured in the DEF-CS system and differentiated into definitive endoderm cells. The cells were then transferred to a 3D bioreactor and further matured into hepatocyte-like cells.
- Ulvestad, M. et al. Drug metabolizing enzyme and transporter protein profiles of hepatocytes derived from human embryonic and induced pluripotent stem cells. Biochem Pharmacol. 86(5):691–702 (2013).
Human embryonic stem cells and pluripotent stem cells were maintained and expanded in the DEF-CS system prior to differentiation into hepatocytes. Following differentiation, the researchers characterized the expression and function of important CYP enzymes and transporter proteins in the differentiated cells.
- Valton, J. et al. Efficient strategies for TALEN-mediated genome editing in mammalian cell lines. Methods. 69(2):151–170 (2014).
Human induced pluripotent stem cells were maintained in the DEF-CS system before and after transfection by DNA electroporation.
- Vizlin-Hodzic, D. et al. Early onset of inflammation during ontogeny of bipolar disorder: the NLRP2 inflammasome gene distinctly differentiates between patients and healthy controls in the transition between iPS cell and neural stem cell stages. Transl Psychiatry. 7(1):e1010 (2017).
Human induced pluripotent stem cells were maintained in the DEF-CS system prior to differentiation into neural stem cells.
- Zandén, C. et al. Stem cell responses to plasma surface modified electrospun polyurethane scaffolds. Nanomedicine. 10(5):949–958 (2014).
Human embryonic stem cells (Y00025) were cultured in the DEF-CS system and plated on coverslips that were coated with various plasma surface modified polyurethane scaffolds. The researchers wanted to investigate the effects of the different modifications on stem cell behavior.
Takara Bio USA, Inc.
United States/Canada: +1.800.662.2566 • Asia Pacific: +1.650.919.7300 • Europe: +33.(0)1.3904.6880 • Japan: +81.(0)77.565.6999
FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES. © 2020 Takara Bio Inc. All Rights Reserved. All trademarks are the property of Takara Bio Inc. or its affiliate(s) in the U.S. and/or other countries or their respective owners. Certain trademarks may not be registered in all jurisdictions. Additional product, intellectual property, and restricted use information is available at takarabio.com.